Switch theme
Sign up to access all valuation multiples
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
2016
88K+
LTM Revenue $15.7B
LTM EBITDA $3.7B
$36.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
IQVIA has a last 12-month revenue (LTM) of $15.7B and a last 12-month EBITDA of $3.7B.
In the most recent fiscal year, IQVIA achieved revenue of $15.4B and an EBITDA of $3.5B.
IQVIA expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IQVIA valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $15.7B | XXX | $15.4B | XXX | XXX | XXX |
| Gross Profit | $5.5B | XXX | $5.4B | XXX | XXX | XXX |
| Gross Margin | 35% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | $3.7B | XXX | $3.5B | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $3.1B | XXX | $2.3B | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $2.1B | XXX | $1.4B | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $12.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, IQVIA's stock price is $140.
IQVIA has current market cap of $24.3B, and EV of $36.9B.
See IQVIA trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $36.9B | $24.3B | XXX | XXX | XXX | XXX | $11.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, IQVIA has market cap of $24.3B and EV of $36.9B.
IQVIA's trades at 2.4x EV/Revenue multiple, and 10.7x EV/EBITDA.
Equity research analysts estimate IQVIA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IQVIA has a P/E ratio of 11.8x.
See valuation multiples for IQVIA and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $24.3B | XXX | $24.3B | XXX | XXX | XXX |
| EV (current) | $36.9B | XXX | $36.9B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 9.9x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBIT | 11.8x | XXX | 16.3x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.8x | XXX | 17.7x | XXX | XXX | XXX |
| EV/FCF | 17.7x | XXX | 17.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIQVIA's last 12 month revenue growth is 5%
IQVIA's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $35K for the same period.
IQVIA's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IQVIA's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for IQVIA and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $35K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IQVIA acquired XXX companies to date.
Last acquisition by IQVIA was XXXXXXXX, XXXXX XXXXX XXXXXX . IQVIA acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was IQVIA founded? | IQVIA was founded in 2016. |
| Where is IQVIA headquartered? | IQVIA is headquartered in United States of America. |
| How many employees does IQVIA have? | As of today, IQVIA has 88K+ employees. |
| Who is the CEO of IQVIA? | IQVIA's CEO is Mr. Ari Bousbib. |
| Is IQVIA publicy listed? | Yes, IQVIA is a public company listed on NYS. |
| What is the stock symbol of IQVIA? | IQVIA trades under IQV ticker. |
| When did IQVIA go public? | IQVIA went public in 2013. |
| Who are competitors of IQVIA? | Similar companies to IQVIA include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of IQVIA? | IQVIA's current market cap is $24.3B |
| What is the current revenue of IQVIA? | IQVIA's last 12 months revenue is $15.7B. |
| What is the current revenue growth of IQVIA? | IQVIA revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of IQVIA? | Current revenue multiple of IQVIA is 2.4x. |
| Is IQVIA profitable? | Yes, IQVIA is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of IQVIA? | IQVIA's last 12 months EBITDA is $3.7B. |
| What is IQVIA's EBITDA margin? | IQVIA's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of IQVIA? | Current EBITDA multiple of IQVIA is 9.9x. |
| What is the current FCF of IQVIA? | IQVIA's last 12 months FCF is $2.1B. |
| What is IQVIA's FCF margin? | IQVIA's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of IQVIA? | Current FCF multiple of IQVIA is 17.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
